Bioceltix S.A. (WSE:BCX)

Poland flag Poland · Delayed Price · Currency is PLN
106.60
+3.60 (3.50%)
Jun 6, 2025, 5:02 PM CET
67.08%
Market Cap 524.95M
Revenue (ttm) n/a
Net Income (ttm) -14.49M
Shares Out 4.92M
EPS (ttm) -3.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,896
Average Volume 8,189
Open 103.00
Previous Close 103.00
Day's Range 101.40 - 106.80
52-Week Range 58.90 - 129.00
Beta 1.45
RSI 45.22
Earnings Date May 29, 2025

About Bioceltix

Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 36
Stock Exchange Warsaw Stock Exchange
Ticker Symbol BCX
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.